Treatment of ADA2 deficiency involves anti-tumor necrosis factor alpha agents, which prevent and eliminate manifestations of autoinflammatory disease, reduce the risk of ischemic stroke, and relieve immunodeficiency.5 This evidence concerns the gene TNF and ischemic stroke.